Pharma BD Deal Intelligence

Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals

2011 · Acquisition/Merger · $700M · Complete

Announcement Sentiment

Neutral / mixed

Valeant acquired iNova Pharmaceuticals from Archer Capital and others for A$625M (~$625M USD) cash plus up to A$75M in milestones (~$700M total). Established Valeant's Australasia/SE Asia commercial platform.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Dec 21, 2011
Closed Dec 22, 2011
Deal value $700M
Deal type Acquisition/Merger
Therapeutic area Pain, weight management, cough/cold, dermatology (multiple)
Indications Pain, weight management, cough/cold, dermatology (multiple)
Key assets Australasia/SE-Asia branded prescription and OTC portfolio (Duromine, Difflam, Coloxyl)
Mechanism Branded specialty pharma multi-product portfolio

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals